SCHEDULE: ARK Investment Management Discloses Twist Bioscience Stake

ARK Investment Management LLC and Catherine D. Wood have filed an amendment to their Schedule 13G, reporting beneficial ownership of 10.35% of Twist Bioscience Corp. common stock as of March 31, 2026.

Summary

• ARK Investment Management LLC and Catherine D. Wood have jointly filed an amendment (Amendment No. 8) to their Schedule 13G filing.
• The filing reports their beneficial ownership of Twist Bioscience Corp. common stock.
• As of March 31, 2026, the aggregate amount beneficially owned is 6,342,733 shares.
• This represents 10.35% of the class of securities.
• ARK Investment Management LLC holds sole voting power for 5,952,949 shares and shared voting power for 96,494 shares.
• Catherine D. Wood holds shared voting power for 6,049,443 shares.
• ARK Investment Management LLC holds sole dispositive power for 6,342,733 shares.
• Catherine D. Wood holds shared dispositive power for 6,342,733 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, indicating continued institutional support and confidence from a prominent growth-focused investor, though it is primarily a disclosure of existing holdings.

Positives

• ARK Investment Management and Catherine D. Wood maintain a significant stake (10.35%) in Twist Bioscience Corp., indicating continued confidence.
• The filing confirms that the shares are held in the ordinary course of business, suggesting a standard investment strategy rather than a hostile takeover attempt.

Risks

• The filing does not explicitly mention any risks. However, any investment in a publicly traded company carries inherent market risks.
• The concentration of ownership by ARK could potentially lead to increased volatility if ARK decides to significantly alter its position.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a disclosure of current ownership.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that ARK Investment Management's continued significant stake in Twist Bioscience Corp. aligns with ARK's strategy of investing in disruptive innovation, particularly within the genomics and synthetic biology sectors. This filing indicates ARK's sustained conviction in Twist Bioscience's long-term potential.

Stakeholder Impact

• Shareholders: The continued significant ownership by ARK may be viewed positively by other shareholders, signaling institutional confidence in the company's prospects. It could also imply potential for future price movements influenced by ARK's trading activity.
• Management: The filing reinforces the existing shareholder structure and does not directly impact management operations, but confirms ARK's role as a major investor.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• ARK Investment Management and Catherine D. Wood will continue to hold their shares in Twist Bioscience Corp.
• Future amendments to this Schedule 13G will be filed if there are material changes in ownership.

Key Dates

Recommendation

This filing is a routine disclosure of beneficial ownership by ARK Investment Management and Catherine D. Wood, confirming their substantial stake in Twist Bioscience Corp. It does not provide new operational or financial performance data that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, pending further company-specific news or performance updates.

Keywords

Twist Bioscience Corp, ARK Investment Management, Catherine D. Wood, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Biotechnology